Provided by Tiger Trade Technology Pte. Ltd.

Crinetics Pharmaceuticals Inc.

84.95
+0.11000.13%
Post-market: 84.970.0200+0.02%19:49 EDT
Volume:8.21M
Turnover:697.41M
Market Cap:9.01B
PE:-16.89
High:85.01
Open:84.96
Low:84.92
Close:84.84
52wk High:85.01
52wk Low:31.00
Shares:106.10M
Float Shares:95.53M
Volume Ratio:8.52
T/O Rate:8.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0290
EPS(LYR):-4.9500
ROE:-42.45%
ROA:-26.28%
PB:7.56
PE(LYR):-17.16

Loading ...

NASDAQ Trade Halt Trading Halted; for Information Requested by NASDAQ at 07:50 Pm

Reuters
·
2 hours ago

Is Crinetics Pharmaceuticals (CRNX) Fully Priced After A 3.9x Run?

Simply Wall St.
·
Aug 30

Crinetics Pharmaceuticals Held Special Shareholder Meeting on Merger Proposal Vote

Reuters
·
Aug 29

Crinetics Supplements Proxy Disclosures for Vertex USD 85-Per-Share Buyout After Shareholder Suits

Reuters
·
Aug 20

Crinetics-Vertex Deal Clears US Antitrust Waiting Period, Other Approvals in Hand

Reuters
·
Aug 14

Crinetics Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says

MT Newswires Live
·
Aug 05

Vertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold

TIPRANKS
·
Aug 04

Crinetics Q2 Revenue Jumps on Palsonify Launch, Withdraws Guidance

Reuters
·
Aug 04

Crinetics Pharmaceuticals Q2 EPS $(1.14) Beats $(1.24) Estimate, Sales $25.118M Beat $14.840M Estimate

Benzinga Earnings
·
Aug 04

Crinetics Q2 FY26 Net Loss Widens to $120.86 Million; Revenue Climbs to $25.12 Million

Reuters
·
Aug 04

Crinetics Pharmaceuticals Q2 Net Income USD -120.855 Million

Reuters
·
Aug 04

Crinetics Pharmaceuticals: Will not be Providing Updated Guidance and is Withdrawing Its Previously Issued Guidance

THOMSON REUTERS
·
Aug 04

Vertex Raises Annual Revenue Forecast on Cystic Fibrosis Drugs Strength

Reuters
·
Aug 04

Crinetics’ ACROBAT Advance Update: What Paltusotine’s Long-Term Data Means for CRNX Investors

TIPRANKS
·
Jul 30

Earning Preview: Crinetics Pharmaceuticals Inc. revenue is expected to increase by 113.89% this quarter, and institutional views are Neutral

Earnings Agent
·
Jul 29

Crinetics Pharmaceuticals Inc : UBS Cuts to Neutral from Buy; Cuts Target Price to $85 from $55

THOMSON REUTERS
·
Jul 28

UBS Downgrades Crinetics Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $85 From $55

MT Newswires Live
·
Jul 28

Crinetics downgraded to Neutral from Buy at UBS

TIPRANKS
·
Jul 28

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

Benzinga_recent_news
·
Jul 22